
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 7.09 | 7.09 | 0.00 |
Shares | 92.91 | 92.91 | 0.00 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 21.65 | 22.70 |
Price to Book | 3.02 | 3.20 |
Price to Sales | 2.11 | 2.15 |
Price to Cash Flow | 6.98 | 12.59 |
Dividend Yield | 0.33 | 0.63 |
5 Years Earnings Growth | 16.50 | 14.01 |
Name | Net % | Category Average |
---|---|---|
Technology | 25.97 | 24.26 |
Industrials | 21.99 | 20.54 |
Healthcare | 21.90 | 19.93 |
Financial Services | 11.62 | 10.08 |
Consumer Cyclical | 9.61 | 11.14 |
Consumer Defensive | 5.01 | 4.46 |
Energy | 3.89 | 3.56 |
Number of long holdings: 69
Number of short holdings: 1
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Champion Homes | US8308301055 | 2.91 | 73.49 | +4.86% | |
Palomar | US69753M1053 | 2.91 | 123.90 | +0.69% | |
Hamilton Lane | US4074971064 | 2.86 | 159.14 | +0.30% | |
Ligand | US53220K5048 | 2.81 | 154.38 | +1.11% | |
Option Care Health | US68404L2016 | 2.73 | 28.49 | -0.18% | |
Shift4 Payments Inc | US82452J1097 | 2.52 | 89.53 | +2.93% | |
JBTMarel | US4778391049 | 2.45 | 143.01 | +1.56% | |
Bellring | US07831C1036 | 2.31 | 39.73 | +2.54% | |
Halozyme | US40637H1095 | 2.23 | 64.11 | +0.12% | |
Vertex | US92538J1060 | 2.18 | 26.20 | +4.30% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Buffalo Discovery | 415.42M | 4.24 | 8.07 | 8.53 | ||
Buffalo Flexible Income | 259.36M | 5.03 | 8.68 | 8.26 | ||
Buffalo International | 243.3M | 5.10 | 2.67 | 7.16 | ||
Buffalo Growth | 84.48M | 25.59 | 8.55 | 12.84 | ||
Buffalo Mid Cap | 65.14M | 13.89 | 3.12 | 9.45 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review